

Natividad Neri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7194759/publications.pdf>

Version: 2024-02-01

62
papers

1,799
citations

331259

21
h-index

276539

41
g-index

65
all docs

65
docs citations

65
times ranked

1652
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of radiotherapy in diffuse large B-cell lymphoma in advanced stages on complete response after administration of cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. Precision Radiation Oncology, 2019, 3, 100-104.	0.4	3
2	Radiotherapy after immunochemotherapy improves outcomes in patients with primary mediastinal large B-cell lymphoma. Precision Radiation Oncology, 2019, 3, 145-148.	0.4	3
3	Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy. Journal of Oncology Pharmacy Practice, 2019, 25, 1682-1686.	0.5	3
4	Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 207-210.	0.2	9
5	Lymphoma and pregnancy. Japanese Journal of Clinical Oncology, 2017, 47, 467-468.	0.6	1
6	Lymphoma and Pregnancy. JAMA Oncology, 2017, 3, 566.	3.4	0
7	TREATMENT OF EARLY STAGES HODGKIN LYMPHOMA DURING PREGNANCY. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, 2018006.	0.5	13
8	Speckle-Tracking Echocardiography to Detect Cardiac Toxicity in Children Who Received Anthracyclines During Pregnancy. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 1-4.	0.2	6
9	Rituximab as Consolidation Therapy Did Not Improve Outcome in Patients with Diffuse Large B-Cell Lymphoma at Complete Response After Dose-Dense Chemotherapy (CHOP-14). Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 107-110.	0.7	0
10	Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. Hematology, 2015, 20, 538-542.	0.7	25
11	Combined therapy in untreated patients improves outcome in Nasal NK/T lymphoma: results of a clinical trial. Medical Oncology, 2013, 30, 637.	1.2	24
12	Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: An analysis of 3,258 patients in a single center. Medical Oncology, 2013, 30, 520.	1.2	16
13	Author's reply: Chemotherapy during first trimester of pregnancy. International Journal of Cancer, 2013, 132, 1729-1729.	2.3	4
14	Rituximab in the treatment of diffuse large B-cell lymphoma primary of the lung. Hematology, 2013, 18, 81-84.	0.7	8
15	The Role of Genotype in 104 Cases of Diffuse Large B-Cell Lymphoma Primary of Breast. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 126-129.	0.6	34
16	Aggressive chemotherapy in frail patients with diffuse large B-cell lymphoma: The role of pegylated liposomal doxorubicin. Journal of Hematological Malignancies, 2012, 2, .	0.0	0
17	Hematological malignancies and pregnancy: Treat or no treat during first trimester. International Journal of Cancer, 2012, 131, 2678-2683.	2.3	55
18	Multiple myeloma and pregnancy. American Journal of Hematology, 2011, 86, 81-82.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Diffuse large B-cell lymphoma primary of lung. <i>Hematology</i> , 2011, 16, 110-112.	0.7	40
20	ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 125-128.	0.2	21
21	Rituximab and Chemotherapy in Primary Gastric Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 25-28.	0.7	30
22	Rituximab and Dose-Dense Chemotherapy in Primary Testicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 386-389.	1.4	24
23	Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. <i>Medical Oncology</i> , 2008, 25, 360-364.	1.2	12
24	Interferon and Low Dose Methotrexate Improve Outcome in Refractory Mycosis Fungoides/Sézary Syndrome. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 836-840.	0.7	33
25	Rituximab and Escalated Chemotherapy in Elderly Patients with Aggressive Diffuse Large-Cell Lymphoma: A Controlled Clinical Trial. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 194-199.	0.7	14
26	Rituximab and dose dense chemotherapy in primary breast lymphoma. <i>Haematologica</i> , 2007, 92, 1147-1148.	1.7	51
27	Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. <i>Medical Oncology</i> , 2007, 24, 85-89.	1.2	18
28	Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. <i>Medical Oncology</i> , 2007, 24, 227-230.	1.2	106
29	Surgery and Chemotherapy versus Chemotherapy as Treatment of High-Grade MALT Gastric Lymphoma. <i>Medical Oncology</i> , 2006, 23, 295-300.	1.2	14
30	Addition of a Short Course of Chemotherapy Did Not Improve Outcome in Patients with Localized Marginal B-Cell Lymphoma of the Orbit. <i>Oncology</i> , 2006, 70, 173-176.	0.9	25
31	Expression of bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 665-673.	0.6	2
32	Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Stomach: Results of a Controlled Clinical Trial. <i>Medical Oncology</i> , 2005, 22, 057-062.	1.2	82
33	Residual Disease After Chemotherapy in Aggressive Malignant Lymphoma: The Role of Radiotherapy. <i>Medical Oncology</i> , 2005, 22, 383-388.	1.2	41
34	Novel therapy in multiple myeloma. <i>Investigational New Drugs</i> , 2005, 23, 411-415.	1.2	7
35	Primary Breast Lymphoma: Results of a Controlled Clinical Trial. <i>Oncology</i> , 2005, 69, 256-260.	0.9	140
36	Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 1023-1028.	0.6	50

#	ARTICLE	IF	CITATIONS
37	Maintenance Therapy with Interferon- β 2b, Cyclophosphamide, and Prednisone in Aggressive Diffuse Large Cell Lymphoma. <i>Stem Cells and Development</i> , 2004, 13, 205-209.	1.1	5
38	Gemcitabine and Cisplatin in Refractory Malignant Lymphoma. <i>Oncology</i> , 2004, 66, 197-200.	0.9	19
39	Testicular Lymphoma: Organ-Specific Treatment Did Not Improve Outcome. <i>Oncology</i> , 2004, 67, 211-214.	0.9	29
40	Intensive Chemotherapy in the Treatment of Aggressive Diffuse Large B-Cell Lymphoma: Malignant Lymphoma. <i>Medical Oncology</i> , 2004, 21, 269-272.	1.2	6
41	Interferon Alpha 2b as Maintenance Therapy Improves Outcome In Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 2247-2251.	0.6	17
42	In Vitro Proliferation and Expansion of Hematopoietic Progenitors from Patients with Diffuse Large B-Cell Lymphoma Before and After Chemotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 1247-1254.	0.6	6
43	The Role of Surgery in Primary Gastric Lymphoma. <i>Annals of Surgery</i> , 2004, 240, 44-50.	2.1	148
44	Nasal NK/T-Cell Lymphoma with Disseminated Disease Treated with Aggressive Combined Therapy. <i>Medical Oncology</i> , 2003, 20, 13-18.	1.2	33
45	No Association Between Lymphoma and Hepatitis C Virus. <i>Medical Oncology</i> , 2003, 20, 165-168.	1.2	10
46	Treatment of Advanced Hodgkin's Disease: EBVD versus Intensive Brief Chemotherapy. <i>Leukemia and Lymphoma</i> , 2003, 44, 1361-1365.	0.6	5
47	Lack of Prognostic Factors in Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 143-147.	0.6	6
48	Spinal Cord Compression as a Primary Manifestation of Aggressive Malignant Lymphomas: Long-term Analysis of Treatments with Radiotherapy, Chemotherapy or Combined Therapy. <i>Leukemia and Lymphoma</i> , 2002, 43, 355-359.	0.6	15
49	Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. <i>European Journal of Haematology</i> , 2002, 68, 144-149.	1.1	20
50	Large bowel lymphoma: An analysis of prognostic factors and therapy in 53 patients. <i>Journal of Surgical Oncology</i> , 2002, 80, 111-115.	0.8	32
51	Pegylated Liposomal Doxorubicin in Combination Chemotherapy in the Treatment of Previously Untreated Aggressive Diffuse Large-B-Cell Lymphoma. <i>Medical Oncology</i> , 2002, 19, 55-58.	1.2	20
52	Chemotherapy Plus Interferon- β 2b Versus Chemotherapy in the Treatment of Follicular Lymphoma. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 669-674.	1.8	7
53	Randomized Clinical Trial to Evaluate Maintenance Therapy in Diffuse Large Cell Lymphoma Treated with Intensive Chemotherapy. <i>Hematology</i> , 2001, 5, 435-440.	0.7	1
54	Hematological Malignancies and Pregnancy: A Final Report of 84 Children Who Received Chemotherapy In Utero. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 173-177.	2.1	375

#	ARTICLE	IF	CITATIONS
55	Treatment of Refractory Hodgkin's Disease with Modified Stanford V Program. <i>Medical Oncology</i> , 2001, 18, 261-268.	1.2	5
56	Evaluation on a Six-Dose Treatment of Anti CD 20 Monoclonal Antibody in Patients with Refractory Follicular Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2001, 16, 159-162.	0.7	5
57	Late Lethal Events in Patients with Diffuse Large B Cell Lymphoma: a Review of 714 Patients Treated in a Single Centre. <i>Leukemia and Lymphoma</i> , 2001, 42, 631-637.	0.6	9
58	Rituximab in the Treatment of Refractory Follicular Lymphoma - Six Doses Are Better Than Four. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 313-316.	1.8	11
59	Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens. <i>European Journal of Haematology</i> , 2001, 66, 94-99.	1.1	13
60	Second Lethal Events Associated with Treatment for Hodgkin's Disease: A Review of 2980 Patients Treated in a Single Mexican Institute. <i>Leukemia and Lymphoma</i> , 2000, 39, 311-319.	0.6	15
61	In Vitro Hematopoiesis in Patients with Malignant Lymphoma During Active Disease and at Complete Clinical Remission After Chemotherapy. <i>Leukemia and Lymphoma</i> , 2000, 39, 613-624.	0.6	1
62	Interferon as Maintenance Therapy in Refractory Malignant Lymphoma. <i>Stem Cells and Development</i> , 1999, 8, 263-267.	1.0	4